These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21603651)

  • 21. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
    Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
    PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
    Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
    J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
    Hayes P; Gilmour J; von Lieven A; Gill D; Clark L; Kopycinski J; Cheeseman H; Chung A; Alter G; Dally L; Zachariah D; Lombardo A; Ackland J; Sayeed E; Jackson A; Boffito M; Gazzard B; Fast PE; Cox JH; Laufer D
    Clin Vaccine Immunol; 2013 Mar; 20(3):397-408. PubMed ID: 23345581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
    J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.
    Hirao LA; Wu L; Khan AS; Hokey DA; Yan J; Dai A; Betts MR; Draghia-Akli R; Weiner DB
    Vaccine; 2008 Jun; 26(25):3112-20. PubMed ID: 18430495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.
    Munusamy Ponnan S; Pattabiram S; Thiruvengadam K; Goyal R; Singla N; Mukherjee J; Chatrath S; Bergin P; T Kopycinski J; Gilmour J; Kumar S; Muthu M; Subramaniam S; Swaminathan S; Prasad Tripathy S; Luke HE
    PLoS One; 2019; 14(3):e0213911. PubMed ID: 30921340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
    Vasan S; Schlesinger SJ; Chen Z; Hurley A; Lombardo A; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Boente-Carrera M; Schmidt C; Fang Q; LeiBa ; Huang Y; Zaharatos GJ; Gardiner DF; Caskey M; Seamons L; Ho M; Dally L; Smith C; Cox J; Gill D; Gilmour J; Keefer MC; Fast P; Ho DD
    PLoS One; 2010 Jan; 5(1):e8816. PubMed ID: 20111599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
    Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
    PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
    Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
    J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.
    Tavel JA; Martin JE; Kelly GG; Enama ME; Shen JM; Gomez PL; Andrews CA; Koup RA; Bailer RT; Stein JA; Roederer M; Nabel GJ; Graham BS
    J Acquir Immune Defic Syndr; 2007 Apr; 44(5):601-5. PubMed ID: 17325604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
    Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
    Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Wilson GJ; Rodriguez B; Li SS; Allen M; Frank I; Rudnicki E; Trahey M; Kalams S; Hannaman D; Clarke DK; Xu R; Egan M; Eldridge J; Pensiero M; Latham T; Ferrari G; Montefiori DC; Tomaras GD; De Rosa SC; Jacobson JM; Miner MD; Elizaga M;
    Vaccine; 2023 Apr; 41(16):2696-2706. PubMed ID: 36935288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
    García F; Bernaldo de Quirós JC; Gómez CE; Perdiguero B; Nájera JL; Jiménez V; García-Arriaza J; Guardo AC; Pérez I; Díaz-Brito V; Conde MS; González N; Alvarez A; Alcamí J; Jiménez JL; Pich J; Arnaiz JA; Maleno MJ; León A; Muñoz-Fernández MA; Liljeström P; Weber J; Pantaleo G; Gatell JM; Plana M; Esteban M
    Vaccine; 2011 Oct; 29(46):8309-16. PubMed ID: 21907749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
    Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
    J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
    Launay O; Durier C; Desaint C; Silbermann B; Jackson A; Pialoux G; Bonnet B; Poizot-Martin I; Gonzalez-Canali G; Cuzin L; Figuereido S; Surenaud M; Ben Hamouda N; Gahery H; Choppin J; Salmon D; Guérin C; Bourgault Villada I; Guillet JG;
    PLoS One; 2007 Aug; 2(8):e725. PubMed ID: 17712402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
    Munseri PJ; Kroidl A; Nilsson C; Joachim A; Geldmacher C; Mann P; Moshiro C; Aboud S; Lyamuya E; Maboko L; Missanga M; Kaluwa B; Mfinanga S; Podola L; Bauer A; Godoy-Ramirez K; Marovich M; Moss B; Hoelscher M; Gotch F; Stöhr W; Stout R; McCormack S; Wahren B; Mhalu F; Robb ML; Biberfeld G; Sandström E; Bakari M
    PLoS One; 2015; 10(4):e0119629. PubMed ID: 25875843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses.
    Bråve A; Nyström S; Roos AK; Applequist SE
    Immunol Cell Biol; 2011 Mar; 89(3):492-6. PubMed ID: 20838412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.